Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling

INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Lung Cancer
Главные авторы: Le, Xiuning, Freed, Jason A., VanderLaan, Paul A., Huberman, Mark S., Rangachari, Deepa, Jorge, Susan E., Lucena-Araujo, Antonio R., Kobayashi, Susumu S., Balasubramanian, Sohail, He, Jie, Chudnovksy, Yakov, Miller, Vincent A., Ali, Siraj M., Costa, Daniel B.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/
https://ncbi.nlm.nih.gov/pubmed/25922291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы